3 employees
TolerogenixX GmbH has developed a patented and clinically
2016
$7.6M
from 3 investors over 3 rounds
TolerogenixX GmbH raised $7.6M on July 6, 2023
Investors: High-Tech Gründerfonds and Kalodion GmbH
TolerogenixX GmbH raised undisclosed on May 23, 2017
Investors: High-Tech Gründerfonds